Basics: short version, verdict first People Molecules Peptides Biomarkers Studies Stem Cells Editorial Methodology
Layer 1 · Decision
← All products
Elysium Health

Basis

Longevity stack · Capsule · 30 servings
Editorial noteBasis is 250 mg NR plus 50 mg pterostilbene per two-capsule serving at USD 40-60 per month. The only trial of the exact formula (Dellinger 2017, N=120) was Elysium-funded and measured a NAD+ biomarker rise, not a clinical outcome. No head-to-head study has shown pterostilbene + NR beats plain NR. See the Elysium brand page for the ChromaDex litigation record (Federal Circuit 2023, C.D. Cal. 2017, SDNY 2022) and the BBB NAD 2020 ruling that any anti-aging benefits have not been shown in humans.

Label snapshot

What the label says

What the product contains and what one serving costs, according to our catalog. Label amounts are not personal dose recommendations.

Ingredients listed
2 ingredients listed largest listed: NR 250 mg
Form
Capsule
List price (catalog, USD)
$60.00
Price per serving
$2.00List price divided by servings per container. A per-day cost only if the label serving is once daily.

Reading notes

  • Multi-ingredient product. Amounts are per ingredient per serving; the product is assessed as one bundle, not as a recommendation for each ingredient.
Full label record: servings, testing, ingredients
Servings per container
30
Serving size (label)
0.4 g
Catalog monthly estimate
$60.00
Testing disclosure
Brand lists third-party testing; no public lab certificate listedStatus as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.

Ingredients as listed

IngredientAmount per serving
NR250 mg
Pterostilbene50 mg

What to check on the label

  • Whether every ingredient has its own milligram line, or several are grouped in a 'blend' with one total.
  • How many capsules or scoops make a serving, and how many servings the container holds.
  • Whether the ingredients you care about appear at amounts you would accept on their own. The list below shows each figure.

Amounts are per label serving as recorded in the catalog and are not a recommendation. Testing status reflects what the brand lists. Nothing here is medical advice.

Editorial score and research-dose calculations

These calculations describe our scoring method. They are not a recommended dose or proof of benefit from this product.

6.8/10
Overall score
#2 / 16 in Longevity stack

Tested by independent lab.

Read the evidence (3 studies)
Add to compareVisit brand site →
Watch out
Tier 2
Product RCT (not peer-reviewed)
Product-specific RCT exists but was not peer-reviewed.
See the 3 supporting studies
  • Martens et al. 2018 (NR)6 weeks of 500 mg twice daily lowered systolic blood pressure in older adults with elevated BP. Studied at 500 mg. This product: 250 mg.
  • Dellinger et al. 2017 (NR)8 weeks at 100 to 1000 mg/day dose-dependently raised NAD+ in blood. Studied at 1000 mg. This product: 250 mg.
  • Riche et al. 2013 (Pterostilbene)12 weeks of 250 mg/day lowered blood pressure but raised LDL. Studied at 250 mg. This product: 50 mg.
How we scored this product Show the full breakdown
Dose vs. studies (50%) Why 7.0 of 10. Primary ingredient is NR (evidence grade B). It delivers 250 mg, inside the studied range of 100–1000 mg. Read the rule → 7.0
Transparency (20%) Why 7.0 of 10. Earned points for independent third-party testing and all doses disclosed. Lost points for no public certificate of analysis. Read the rule → 7.0
Value (10%) Why 6.7 of 10. One day at the trial dose costs about $2.40. That is more expensive than average (213 of 313 by cost per effective day). Read the rule → 6.7
Formulation (10%) Why 5.0 of 10. No published absorption advantage or disadvantage on file. The default of 5 is not a criticism. Read the rule → 5.0 Default. No absorption data on file.
Safety (5%) Why 7.0 of 10. Baseline 5.0. Third-party testing adds 2.0. Public lab certificate adds 1.5. NSF, USP or Informed Choice certification adds 1.5. Active safety signal subtracts 3.0. Read the rule → 7.0
Community sentiment (5%) Why 7.7 of 10. Sentiment across 12 external review source(s) is mixed to positive. Community is a signal about daily use, not proof of effect. Read the rule → 7.7
Composite How this 6.8 is built. 0.50 × 7.0 + 0.20 × 7.0 + 0.10 × 6.7 + 0.10 × 5.0 + 0.05 × 7.0 + 0.05 × 7.7 = 6.8 out of 10. Safety caps applied after. 6.8
6.8 composite
Dose vs. studies50%7.0
Transparency20%7.0
Value10%6.7
Formulation10%5.0
Safety5%7.0
Community5%7.7

Evidence gates dose: the evidence grade sets the ceiling, and the dose decides how much of that ceiling the product reaches. Value = inverse of price-per-trial-dose-day. Community = mean sentiment of external reviews. Safety caps applied after weighting.

This score is our editorial judgment, not a scientific standard. We combine published evidence, dose, price, transparency, and consumer signals into one composite: this is our method, not a peer-reviewed clinical rating. A higher score means a product does better on the factors we weight, not that it is medically proven to work.

Read the full method →

Editorial verdict

Quick verdict

6.8 / 10
Best for
Full trial dose
Avoid if
No public lab certificate
Full-dose status
Meets trial dose
Price/month
$60
COA status
Not public
Biggest caveat
No public lab certificate available for independent verification.
Nearest alternatives
Catalog snapshot. Check linked sources for current price, label and batch-specific testing.
Price verification
Current price: $60.00
Last price check: Sep 01, 2026
Add to compareVisit brand site →
Layer 2 · Context

Our summary

Elysium Basis is an NR + pterostilbene combination supplement (250 mg NR + 50 mg pterostilbene per 2-capsule serving) from a company founded by MIT aging researcher Leonard Guarente, and it is the product behind the most-cited human NAD+ trial in this category, Dellinger et al. 2017, a randomized, double-blind, placebo-controlled study run by an independent CRO on the exact label dose. That trial supports the vendor's headline '40% NAD+ increase' claim, but it was fully funded by Elysium and authored entirely by Elysium employee-shareholders, which caps it at Tier 2 rather than Tier 1, and it measures a biomarker rather than a health outcome. Basis also carries genuine third-party quality backing (NSF Certified for Sport) and survived years of patent and trade-secret litigation with its original ingredient supplier, ChromaDex, though a jury did find Elysium liable for breaching that supply agreement. Buyers should treat the NAD+ increase claim as real but sponsor-generated, and should note that independent, non-sponsor evidence specifically on Basis, from ConsumerLab, Trustpilot, or major consumer-health outlets, is either inaccessible or too thin to corroborate or refute the vendor's claims independently.
In plain language

Why this scored this way

This Elysium Health Basis scores 6.8, making it a mid-tier product with both strengths and weaknesses. It delivers 250mg of NR, inside the studied range of 100–1000mg with grade B evidence (promising human data, not yet comprehensive). At $2.40/day it's among the more expensive options in Longevity stack.

What drives the score up

  • Dose-evidence score of 7.0 shows decent alignment with trial doses.
  • Tested by independent lab (transparency 7.0).
  • NR is dosed at the full research level with grade B evidence (promising human data, not yet comprehensive).

What drags it down

  • No public lab certificate available for independent verification.
  • At $2.40/day it's on the expensive side.

Why you'd choose it

  • You want NR from a Elysium Health product.
  • You want a tested by independent lab product.
  • You want doses that align with published research.

Why you might skip it

  • You want a product with a publicly available CoA.
  • You want a cheaper option (this is $2.40/day).
Question 1

Does the molecule work?

The science behind each active ingredient, independent of which brand sells it.

NR

The NAD+ precursor with the strongest safety file and EU approval.

2 landmark RCTs · US: GRAS, NDI accepted · EU: Authorised Novel Food (Commission Reg 2020/16)
Pterostilbene

Resveratrol's more bioavailable cousin, mostly used in blends.

1 landmark RCT · US: Dietary supplement · EU: Food supplement

Full ingredient breakdown

Every active in this formula, its declared dose per serving, the dose used in the primary human trial, how much of that trial dose this product delivers, and the evidence grade for the ingredient itself.

IngredientDose / servingResearch dose% of researchEvidence grade
NR250 mg300 mg83%B
Pterostilbene50 mg100 mg50%D

Percentages are dose per serving ÷ primary trial dose. Below 50% means the formula is unlikely to reproduce the trial outcome for that active. Grade A = multiple large human RCTs. Grade F = no human evidence. How grades work. Full glossary →

Question 2

Is this bottle good?

The specific product: dose, price, transparency, and what buyers report.

Dose vs research
100% of trial dose
Meets or exceeds the published effective dose
Cost at trial dose
$2.40/day at trial dose
What one effective daily dose actually costs
Transparency
7.0/10 · No public lab certificate
Independent batch testing confirmed
Consumer signals
11,020 reviews across platforms · 4.4/5 · high confidence
Operational signal only, never used as clinical evidence
Question 3

What's the catch?

Safety flags, transparency gaps, dosing concerns, and recurring buyer complaints.

No public lab certificate
Certificate of Analysis not published
Without a public lab certificate, batch purity and potency cannot be independently verified.
Buyer complaints
Reddit: Community view: pioneering but out-competed on both price and dose since 2023.
Recurring themes from consumer review platforms.
Plain English

What’s inside

The main ingredients of this product, in plain language.

NR250 mgEvidence B

The NAD+ precursor with the strongest safety file and EU approval.

Read about NR →
Pterostilbene50 mgEvidence D

Resveratrol's more bioavailable cousin, mostly used in blends.

Read about Pterostilbene →
Layer 3 · Evidence vault

Product data & verification

Hard numbers and independently checked status. Expand each block for its source.

The numbers

Price
$60
per bottle · 30 servings
Dose vs. research
of trial dose 100%
of published effective dose
$ / day at studied dose
$2.40
what one effective daily dose costs
$ / g active
$6.67
per gram of active substance
Independently checked

Data verification

COA status
Not public
Evidence grade
BD
Per-ingredient breakdown
BNR
DPterostilbene

All product data is checked against original sources. Prices, doses, and testing status are updated when product pages change. Evidence grades are reviewed when new human RCTs are published. Read how we verify.

What's inside

Ingredient
Dose in this product
Trial dose
Evidence
NR
The NAD+ precursor with the strongest safety file and EU approval.
Martens et al. 2018Dellinger et al. 2017
250 mg 83% of trial dose
300 mg
Pterostilbene
Resveratrol's more bioavailable cousin, mostly used in blends.
Riche et al. 2013
50 mg 50% of trial dose
100 mg
3.9 /5
High confidence
12,284 reviews across 5 platforms (5 sources)
Source diversity: 100%
AmazonElysium Health (brand site)LabdoorRedditTrustpilot
ComplaintsCommunity view: pioneering but out-competed on both price and dose since 2023.
Last checked: 2026-08-23

Consumer signals

4.4 out of 5 across 11,020 verified reviews on 5 platforms.

High confidence

Consumer sentiment compiled from 2 public sources (Labdoor, Reddit).

Labdoor

3.8/5 · mixed sentiment

Themes

Labdoor passed on purity; docked for under-dosing versus 2026 research levels.

Compiled from a Labdoor listing located during manual research; not independently re-verified against the live page at build time. Rating converted from 100-point to 5-point scale.

Reddit

1 thread discussed · negative sentiment

Complaints

Community view: pioneering but out-competed on both price and dose since 2023.

Compiled from a Reddit r/longevity listing located during manual research; not independently re-verified against the live page at build time.

Trustpilot

15 reviews · 3.2/5

Amazon (search aggregate)

11,005 reviews · 4.4/5

Elysium Health (brand site)

1,264 reviews

These are consumer sentiment signals. They do not measure whether the product actually works. See our evidence section for that.

Independent external anchors

Public sources on this same product, unrelated to NO1GEVITY. NIH DSLD is the US government's registered label database (shown verbatim). SuppCo.com is a separate, unaffiliated commercial site with no partnership or data-sharing arrangement with us. NO1GEVITY scores are computed independently of both.

Unaffiliated third-party site
SuppCo.com

SuppCo is a separate, unaffiliated supplement-tracking site with no partnership, data-sharing agreement, or business relationship with NO1GEVITY. We are not endorsed by them and they do not endorse us. The two facts below are individually verified against the manufacturer or NSF; the outbound link is provided only so readers can independently cross-check on a third-party site if they want to.

Tested by independent lab, Yes

What others say, with a source hierarchy

We treat external opinion very differently depending on where it comes from. Tier A is our strongest signal. Tier C is background sentiment only. Tier Rejected is what we excluded, listed openly so you can see what we discarded.

These reviews are aggregated from third-party sources, not written by NO1GEVITY. Each entry shows its source, retrieval date, and whether the source has an affiliate or paid relationship. We do not edit reviews to change their meaning. Disclosure policy.

Tier A

Independent deep reviews, lab tests, certificates of analysis

Our strongest external evidence. Long-form independent reviews, physical-product lab work, and third-party certifications.

ConsumerLab
No affiliate relationship Not a paid placement

ConsumerLab maintains a page covering Elysium, but the substantive test results and ratings sit behind a paid membership wall.

Finding: Not accessible, full report is members-only
How we use it: Classified as Tier A in principle (ConsumerLab is a legitimate independent lab-testing organization), but we could not extract any specific findings; treated as unverified rather than cited as supporting or refuting evidence.
New York Times (general longevity-supplement coverage, not Basis-specific)
No affiliate relationship Not a paid placement

General-category skepticism: longevity supplements as a class lack proof of lifespan extension in humans, and the sector is described as under-regulated.

Finding: No Basis-specific figures; six consulted medical professionals/researchers stated that no supplement has been proven to extend human lifespan in substantial clinical studies
How we use it: Used only as category-level context on the state of longevity-supplement evidence broadly; does not mention Basis or Elysium by name, so it cannot be used as product-specific evidence.
ALSUntangled (No. 42), Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration journal
No affiliate relationship Not a paid placement

An independent academic patient-advocacy group assessed NRPT/Basis specifically for ALS use and concluded they could not recommend it for that condition due to a total absence of preclinical ALS models, case reports, or ALS-patient trials, while corroborating the safety data from the Dellinger trial.

Finding: Confirmed no serious adverse events in the Dellinger 2017 8-week trial; only 'mild diarrhea' reported at the higher (2X) dose; noted a cost of roughly $1/capsule
How we use it: Used to corroborate the short-term safety profile reported in Dellinger 2017 via an independent academic source; explicitly not used as efficacy evidence, since the ALSUntangled review is about ALS treatment potential, not general healthy-aging benefit.
Tier B

Registered dietitians and physicians, without affiliate ties

Credentialed commentary from clinicians who disclose no paid relationship. Useful as supporting critique but not a substitute for a clinical outcome trial.

The Nad Review (comparison/review site)
Has affiliate relationship Not a paid placement

Describes Basis as a legitimate, trial-backed, third-party-certified product but poor value relative to competitors on a cost-per-dose basis.

Finding: Estimated annual cost of roughly $480 to 720/year for Basis versus $240 to 420/year for competing NR products
How we use it: Used with disclosure as a Tier B affiliate-model comparison source for relative pricing context only; not used for efficacy claims.
Rejected

Sources we transparently discard

Marketing-quoted press, obviously fabricated aggregate ratings, or heavy-affiliate 'reviews'. Listed openly so you can see what we excluded.

Innerbody (comparison table, not a dedicated teardown)
Has affiliate relationship Not a paid placement

The page is a review of Innerbody's own competing NAD+ supplement, with Basis appearing only in a pricing/dose comparison table, not as an independently tested product.

Finding: Basis listed at roughly $40/pouch, 250 mg NR per serving, ≈$5.33 per gram of active ingredient, the highest cost-per-gram among the NAD-precursor products compared
How we use it: Rejected as an independent teardown because Innerbody sells a directly competing product on the same page; the pricing data point is noted only as third-party-sourced context on relative cost, not as an endorsement or independent evaluation of Basis.
Trustpilot
No affiliate relationship Not a paid placement

Very small, inconsistent sample; recent visible feedback centers on subscription billing problems (irregular shipment frequency, difficulty cancelling) rather than product efficacy.

Finding: Review count and rating are inconsistent across snapshots (roughly 6 to 34 reviews; ratings clustering around 2.0 to 3.4/5); one visible June 2024 review described billing/subscription complaints and raised quality concerns
How we use it: Rejected as Tier B evidence because N is far below the site's N>500 threshold for treating Trustpilot as reliable; referenced only qualitatively, as a data gap, not as a quantitative satisfaction score.

Community threads and aggregate ratings

Additional public mentions we located, kept separate from the deep independent reviews above.

Labdoor · 76
mixed

Labdoor passed on purity; docked for under-dosing versus 2026 research levels.

Read source → Unverified · we received no payment for this listing
Reddit r/longevity
negative

Community view: pioneering but out-competed on both price and dose since 2023.

Read source → Unverified · we received no payment for this listing
Layer 3 · Evidence vault

Evidence, claims & regulation

Published evidence, claim checks, regulatory status and what could not be verified.

Evidence, what actually backs this product

Longevity brands rarely test their exact finished product. We separate what's tested from what's inferred.

Strongest evidence tier
Tier 2Product RCT (not peer-reviewed)
2 studies mapped
Tier 2Product RCT (not peer-reviewed)
Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely and sustainably: a randomized, double-blind, placebo-controlled study
Dellinger RW, Santos SR, Morris M, Evans M, Alminana D, Guarente L, Marcotulli E · 2017 · npj Aging and Mechanisms of Disease · n=120 · 250 mg NR + 50 mg pterostilbene/day (NRPT 1X, the exact Basis label dose); a second arm tested 500 mg NR + 100 mg pterostilbene/day (NRPT 2X) · 8 weeks treatment + 30-day follow-up
on this exact productpeer-reviewed
The 1X (label-dose) arm raised blood NAD+ by an average of 40% at day 30, sustained through day 60; the 2X arm rose ~90% but partially declined by day 60. No serious adverse events; one possibly-related case of nausea in the 1X group.
This is the exact Basis formulation and exact label dose (250 mg NR + 50 mg PT), randomized, double-blind, placebo-controlled, and run through an independent CRO (KGK Synergize). However, the trial was fully funded by Elysium, all six named authors were Elysium employees and shareholders at the time (disclosed in the paper), and Elysium supplied both the placebo and investigational product. A 2018 correction (npj Aging Mech Dis. 2018;4:8) added missing product-sourcing disclosures. Endpoint measured is a biomarker (blood NAD+), not a clinical/health outcome.
Conflicts: Sponsored and fully funded by Elysium Health; all six authors were Elysium employees and shareholders; sponsor supplied placebo and product.
Source →
Tier 4Ingredient RCT (different dose)
Nicotinamide riboside is uniquely and orally bioavailable in mice and humans
Trammell SAJ, Schmidt MS, Weidemann BJ, Redpath P, Jaksch F, Dellinger RW, Li Z, Abel ED, Migaud ME, Brenner C · 2016 · Nature Communications · n=12 · Single oral doses of 100 mg, 300 mg, and 1000 mg NR (no pterostilbene tested), 7-day washout between doses · Single-dose pharmacokinetic study (acute, not chronic)
ingredient-levelpeer-reviewed
NR was shown to be safely and orally bioavailable, producing a dose-dependent rise in the blood NAD+ metabolome; no serious adverse events; NAAD identified as a sensitive biomarker of NAD+ repletion.
This is a foundational NR pharmacokinetics paper, not a Basis-specific study, it tests NR alone (no pterostilbene) at single acute doses (100/300/1000 mg) rather than Basis's chronic 250 mg/day co-formulation with pterostilbene. Two of the authors (Dellinger, Jaksch) later became Elysium/ChromaDex-affiliated. Useful for establishing that NR itself is orally bioavailable and safe, but does not test the finished Basis product.
Conflicts: Two of nine authors (Dellinger, Jaksch) had industry ties (later Elysium/ChromaDex); academic co-authors from University of Iowa and Dartmouth. Funding sources not fully re-verified in this pass.
Source →
Evidence

Research behind this product

The studies that established the trial dose and evidence grade for each active ingredient in this product. Click through to read the original paper.

NRMartens et al. 2018
NRDellinger et al. 2017
PterostilbeneRiche et al. 2013

Claim check, vendor claims vs. our reading of the evidence

Not medical advice. We list the strongest claims made by the brand and check each against traceable evidence.

Supported
“Basis increases and sustains NAD+ levels by 40%”
This figure comes directly from the sponsor-funded Dellinger et al. 2017 trial's 1X (label-dose) arm, which measured a 40% mean NAD+ increase at day 30, sustained to day 60 (evidence_registry, Tier 2). The number is accurately quoted, but it reflects a single sponsor-funded trial measuring a biomarker, not an independently replicated or health-outcome finding.
Vendor source
Partial support
“Clinically proven in a double-blind, randomized, placebo-controlled clinical trial”
The trial design (double-blind, randomized, placebo-controlled, N=120) is accurately described and was run by an independent CRO (KGK Synergize). However, 'clinically proven' overstates what a single, sponsor-funded, employee-authored biomarker trial establishes; no independent replication of the NAD+ result on this exact formulation was found.
Vendor source
Supported
“Developed by Dr. Leonard Guarente, MIT sirtuin/aging researcher”
Guarente is a verifiable MIT biology professor and director of the Paul F. Glenn Center for Biology of Aging Research, and multiple independent outlets (MIT Technology Review, New York Magazine/The Cut, Business Insider) confirm his role as Elysium co-founder and chief scientist.
Vendor source
Supported
“NSF Certified for Sport”
Independently confirmed via a 2018 press announcement and NSF/USADA program documentation (https://www.biospace.com/elysium-health-announces-its-cellular-health-product-basis-is-nsf-certified-for-sport). We could not verify a current specific lot certification in this pass, but the certification program itself is real and third-party administered.
Vendor source
Not supported
“Exclusive rights / patent-backed NR technology (as alleged in prior marketing and litigation context)”
ChromaDex alleged in litigation that Elysium falsely represented exclusive patent rights over NR for anti-aging use; separately, the ChromaDex/Dartmouth NR composition patents (US 8,197,807 and 8,383,086) were ultimately invalidated as unpatentable natural phenomena, a ruling affirmed by the Federal Circuit in 2023 (https://fedcircuitblog.com/wp-content/uploads/2023/03/22-1116-Opinion.pdf). No enforceable exclusive NR patent supports Basis's formulation.
Vendor source

Regulatory status

Rules change often. We record when we last verified each row. See the full regulatory timeline →

What we could not verify

We list this openly. If a claim isn't backed by a source we can trace, we'd rather flag it than repeat it.

  • Elysium has never submitted its own New Dietary Ingredient Notification (NDIN) to the FDA for Basis, NR, or pterostilbene as sold in this product, it relies on ChromaDex's ingredient-level NR GRAS/NDI filings rather than a product-specific FDA submission, per court filings in the SDNY litigation (https://www.sdnyblog.com/files/2022/02/ChromaDex.pdf).
  • ConsumerLab's Elysium/Basis page exists but its full test results and ratings are members-only/paywalled; we could not independently verify ConsumerLab's specific findings on Basis (https://www.consumerlab.com/elysium/).
  • Trustpilot's aggregate rating and review count for elysiumhealth.com could not be pinned to one reliable current figure, different snapshots and third-party trackers report anywhere from 6 to 34 reviews and ratings ranging roughly 2.0 to 3.4 out of 5, well under the N>500 threshold this site requires to treat Trustpilot as Tier B evidence (https://www.trustpilot.com/review/www.elysiumhealth.com).
  • No long-term (beyond the ~60-day Dellinger 2017 follow-up window) randomized trial on hard clinical or health-span endpoints (e.g., mortality, disease incidence, physical function) was located for Basis, existing trial data covers only the NAD+ biomarker and short-term safety.
  • Pterostilbene's specific FDA regulatory status (GRAS or NDI) as formulated in Basis was not independently confirmed in this research pass.
  • Innerbody's comparison table places Basis, not a dedicated Innerbody teardown of Basis; the page found during research is primarily a review of Innerbody's own competing NAD+ product, with Basis appearing only as a pricing comparison line item, so no independent Innerbody lab teardown of Basis itself could be verified.
Important to know
NRAlmost all commercial NR uses licensed Niagen® from ChromaDex. If a product doesn't say Niagen, ask why.
PterostilbeneHigh-dose pterostilbene can raise LDL. Keep to <150 mg/day unless working with a clinician.

Editorial notes

The original NR + pterostilbene combo. Under-dosed by 2026 research standards.

Go deeper

Where this sits

Actives inside
NRPterostilbene
Category
See all in Longevity stack →
Ranking
See top 10 NR supplements →
Brand
Elysium Health profile →
Add to compare Visit brand site →
Brand owners

Spot an error?

If you are the manufacturer or brand owner of Basis and believe any data on this page is incorrect (wrong dose, wrong ingredient, wrong price, missing certification, outdated status), you can request a correction.

We review every request, verify it against primary sources, and publish any accepted change with a dated note. Corrections from brand owners are treated the same as corrections from anyone else: verified before they move.

Request a correction →
Same shelf

Similar products

All Longevity stack →

The next highest-scoring products in Longevity stack, same scoring method, same rules.

AG1 (Athletic Greens)
AG Vitamin D3+K2
Longevity stack
Ingredients listed
2 ingredients listedlargest listed: Vitamin K2 100 µg
Price per serving
$0.05$29.00 · 600 servings
Testing
3rd-party listed · no public lab certificate

Multi-ingredient bundle

Status as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.

Score & research context 7.0/10

Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.

100%
of trial dose
$0.10
per research-dose day, not label serving
0Trial dose2×
Catalog price · Confirm current price with drinkag1.com
Longevity stack
Ingredients listed
6 ingredients listedlargest listed: Creatine 2,500 mg
Price per serving
$1.63$49.00 · 30 servings
Testing
3rd-party listed · no public lab certificate

Multi-ingredient bundle

Status as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.

Score & research context 6.7/10

Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.

83%
of trial dose
$3.27
per research-dose day, not label serving
0Trial dose2×
Catalog price · Confirm current price with blueprint.bryanjohnson.com
Aidan Products
Stem-Kine
Longevity stack
Ingredients listed
2 ingredients listedlargest listed: Beta-Glucan 200 mg
Price per serving
$2.00$59.95 · 30 servings
Testing
None listed

Multi-ingredient bundle

Status as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.

Score & research context 6.6/10

Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.

13%
of trial dose
$29.98
per research-dose day, not label serving
0Trial dose2×
Catalog price · Confirm current price with www.stem-kine.com
Same maker

Other products from Elysium Health

Brand profile →
Elysium Health
Signal
NAD+ booster
Precursor per serving
NMN 250 mgCapsule · 30 servings
Price per serving
$1.33$40.00 · 30 servings
Testing
3rd-party listed · no public lab certificate

Undisclosed amounts noted

Status as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.

Score & research context 7.5/10

Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.

100%
of trial dose
$2.67
per research-dose day, not label serving
0Trial dose2×
Catalog price · Confirm current price with www.elysiumhealth.com
Elysium Health
Matter
Cognition
Ingredients listed
4 ingredients listedlargest listed: Omega-3 (EPA/DHA) 550 mg
Price per serving
$1.33$40.00 · 30 servings
Testing
3rd-party listed · no public lab certificate

EPA/DHA split not stored

Status as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.

Score & research context 7.1/10

Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.

100%
of trial dose
$1.33
per research-dose day, not label serving
0Trial dose2×
Catalog price · Confirm current price with www.elysiumhealth.com
Elysium Health
Vision
Antioxidant
Active per serving
Astaxanthin 6 mgSoftgel · 30 servings
Price per serving
$1.33$40.00 · 30 servings
Testing
None listed

Status as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.

Score & research context 6.8/10

Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.

100%
of trial dose
$1.78
per research-dose day, not label serving
0Trial dose2×
Catalog price · Confirm current price with www.elysiumhealth.com
Elysium Health
Format
Antioxidant
Ingredients listed
3 ingredients listedlargest listed: Vitamin C 90 mg
Price per serving
$2.00$60.00 · 30 servings
Testing
3rd-party listed · no public lab certificate

Elemental vs compound: check label

Status as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.

Score & research context 5.9/10

Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.

45%
of trial dose
$11.11
per research-dose day, not label serving
0Trial dose2×
Catalog price · Confirm current price with www.elysiumhealth.com
Elysium Health
Cofactor
Connective tissue
Ingredients listed
4 ingredients listedlargest listed: Collagen Peptides 20 g
Price per serving
$2.68$75.00 · 28 servings
Testing
None listed

Multi-ingredient bundle

Status as recorded in the catalog from brand materials; not independently verified by NO1GEVITY.

Score & research context 5.5/10

Editorial score, not proof that this product works. Research-dose calculations are not dosing advice.

800%
of trial dose
$1.34
per research-dose day, not label serving
800% · over 2× trial dose0Trial dose2×
Catalog price · Confirm current price with www.elysiumhealth.com